Celecoxib in Preventing Breast Cancer in Premenopausal Women
This study is not yet open for patient recruitment.
Sponsored by: |
Southwest Oncology Group
|
Information provided by: |
National Cancer Institute (NCI) |
Purpose
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer.
The use of celecoxib may be effective in preventing breast cancer.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are
at risk for developing the disease.
Condition
|
Treatment or Intervention |
Phase |
Breast Cancer breast cancer in situ lobular breast carcinoma in situ
|
Drug: celecoxib Procedure: biological response modifier therapy Procedure: cancer prevention intervention Procedure: chemoprevention of cancer Procedure: enzyme inhibitor therapy Procedure: prostaglandin inhibition
|
Phase II
|
MedlinePlus related topics: Breast Cancer; Cancer; Cancer Alternative Therapy
Genetics Home Reference related topics: breast cancer
Study Type: Interventional
Study Design: Prevention
Official Title: Phase II Randomized Study of Celecoxib in Premenopausal Women at High Risk for Developing Breast Cancer
Further Study Details:
OBJECTIVES:
- Compare 1-year mammographic density in premenopausal women at high risk for developing breast cancer treated with celecoxib
vs placebo.
- Compare 1-year proliferation of breast epithelial cells, as measured by Ki67 staining, in patients treated with these drugs.
- Compare the expression of other biomarkers, including cyclo-oxygenase-2 (COX-2) enzyme and a marker of apoptosis, in breast
tissue of patients treated with these drugs.
- Compare 1-year plasma levels of insulin-like growth factor (IGF)-1, IGF binding protein-3, and prostaglandin E_2 in patients
treated with these drugs.
- Compare the toxicity of these drugs in these patients.
OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients are stratified according to risk
category (lobular carcinoma vs mutation AND any Gail risk vs Gail risk ≥1.7% but < 5% vs Gail risk ≥ 5%) and prior tamoxifen
use (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral celecoxib twice daily.
- Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 months in the absence of unacceptable
toxicity or diagnosis of cancer.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
DISEASE CHARACTERISTICS:
- At elevated risk of developing breast cancer, as defined by 1 of the following:
- Modified Gail risk at 5 years ≥ 1.7%
- Diagnosis of lobular carcinoma
- Known deleterious mutation of or
- At least 1 breast available for imagery and biopsy
- Has undergone a baseline mammogram with a standard density wedge within 7-14 days after completion of the last menstrual period
AND within 7 days before study entry
- Mammogram normal or benign (BIRADS score 0 or 1)
- No ductal carcinoma
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS: Age
Sex
Menopausal status
- Premenopausal, defined by 1 of the following criteria:
- Last menstrual period < 6 months ago AND no prior bilateral ovariectomy AND not on estrogen replacement therapy
- Prior hysterectomy (with ovaries still in place) AND normal follicle-stimulating hormone levels within 28 days of study entry
Performance status
Life expectancy
Hematopoietic
Hepatic
- Bilirubin < 2.0 times upper limit of normal (ULN)
- SGOT or SGPT < 2 times ULN
- Alkaline phosphatase < 2 times ULN
- INR ≤ 1.5
- PT and PTT normal
Renal
- Creatinine < 2.0 times ULN
Pulmonary
- No asthma after taking aspirin or other NSAIDs
Other
- No known sensitivity to celecoxib
- No allergy to sulfonamides
- No urticaria or allergic-type reactions after taking aspirin or other NSAIDs
- No extreme lactose intolerance
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma of
the cervix, or early bladder cancer (preinvasive transitional cell carcinoma of the bladder)
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy
- More than 5 years since prior biologic therapy for cancer
Chemotherapy
- More than 5 years since prior chemotherapy for cancer
Endocrine therapy
- At least 28 days since prior tamoxifen
- Concurrent hormonal contraception (i.e., pills, patches, or shots) allowed provided contraception was initiated prior to study
entry
Radiotherapy
- No prior radiotherapy to the breast to be studied
Surgery
Other
- At least 7 days since prior anticoagulant therapy
- More than 1 month since prior chronic (more than 7 days duration) daily aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
- Concurrent intermittent aspirin or NSAIDs allowed (no more than 10 days per month)
- No concurrent participation in another clinical trial for treatment or prevention of cancer unless no longer receiving treatment
and is in the follow-up phase
Location
Information
Study chairs or principal investigators
Charles A. Coltman, MD, Study Chair, San Antonio Cancer Institute
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers:
CDR0000377698; SWOG-S0300
Record last reviewed:
September 2004
Record first received:
August 4, 2004
ClinicalTrials.gov Identifier:
NCT00088972Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-20